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Abstract 
Objective: To discuss the current knowledge on the impact of commonly used biologic agents 
(i.e., anti-tumor necrosis factor alpha [anti-TNF-α] and anti-nerve growth factor [anti-NGF]) 
in the management of low back pain. 
Methods: A narrative literature review of studies investigating the use of biologic agents for 
the management of low back pain was conducted. We searched MEDLINE and EMBASE for 
English language publications. A hand-search of reference lists of relevant studies was also 
performed  
Results: Although some observational studies showed that inhibition of TNF-α reduced pain 
and improved function, randomised controlled trials and a meta-analysis failed to 
demonstrate superiority of anti-TNF-α over placebo in this regard. Anti-TNF-α however 
reduced the risk of having invasive procedures such as discectomy and radicular block. 
Conversely, controlled studies showed moderate pain reduction and mild functional 
improvement with anti-NGF administration, but the side-effect profile of anti-NGF was 
unfavorable compared to placebo. 
Conclusions: Overall, anti-cytokine treatments have limited efficacy in patients with chronic 
low back pain. However, larger and better-designed studies may need to be performed in 
specific patient sub-populations. Low back pain is particularly disabling in younger patients. 
This group therefore represent a potential target population for investigating the effectiveness 
of anti-cytokine therapies, especially where other pharmacological and non-pharmacological 
management strategies have failed. 
 
Keywords: anti-nerve growth factor, anti-tumour necrosis factor alpha, biologic drugs, low 
back pain 
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Introduction 
Discomfort in the low back that is severe enough to limit activity can be broadly classed as 
low back pain (LBP) and it is the commonest health problem globally [1]. Thirty-nine percent 
of the general population will have at least one episode in their lifetime [2]. The condition is 
not often associated with serious or life-threatening conditions (~1%) [3]. The majority of the 
cases will resolve within three months, but some do become protracted, leading to significant 
morbidity and financial burden to patients and their carers, and places a disproportionately 
high demand on the overstretched healthcare systems worldwide. 
LBP is often used interchangeably with the term sciatica although the later does not represent 
a specific diagnosis, it is a convenient way to refer to pain in the low back and/or radicular 
pain associated with disk herniation. Although herniated intervertebral disc-induced sciatica 
represents the most common mechanism for LBP [4][4], an important proportion of patients 
may also suffer from chronic pain originating from the lower back and radiating down to the 
leg which is neither related to intervertebral disc-related diseases (IVD) nor does it result 
from nerve-root compression [5]. These symptoms are attributable to referred pain from the 
lower back and account for a significant degree of disability in cases of various low back 
related conditions such as degenerative facet joint disease or foraminal stenosis. It is worth 
noting that imaging-based evidence of disc herniation may be found in asymptomatic patients 
underlying that no clear association between clinical presentation and identifiable pathology 
of the spine could be established in many cases of LBP [6]. Given the heterogeneous 
aetiology of symptoms, specific causes of chronic LBP particularly in the absence of IVD 
and/or radicular pain cannot always be elucidated, involving a complex interrelation between 
anatomic and functional abnormalities in the central nervous system, structural changes in the 
back such as degenerative spinal disease and vertebral joint overload due to atrophy or 
asymmetry of key stabilising muscles in the lumbar spine [7]. Such functional and skeletal 
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abnormalities amplified by psychological and social factors including negative emotions and 
beliefs, job dissatisfaction and unhelpful social support [8], account for the majority of cases 
of chronic LBP which is commonly characterised as “nonspecific”, “idiopathic”, 
“mechanical”, “axial” or due to instability [9].  
In the context of IVD, mechanical nerve root compression has long been considered as the 
major cause of disc-induced radicular pain [10]; recent experimental and clinical observations 
have however contradicted this purely mechanical hypothesis by suggesting a chemical 
element in the pathophysiology [11]. The introduction of nucleolus pulposus - the gelatinous 
core part of the intervertebral disc and the main component of IVD – into epidural space 
induces pain, electrophysiological abnormalities and nerve fibre degeneration even in the 
absence of mechanical stimuli (Olmarker’s model) [12, 13]. Animal-model experiments have 
shown that nucleus pulposus exerts significant inflammatory properties resulting in the 
abnormal production of proinflammatory cytokines, amplification of inflammatory responses 
and recruitment of immune cells to the disc; processes that are highly involved in the generation 
of pain (Figure 1) [14, 15]. Advances in experimental and clinical research have led to the 
development of biologic agents targeting specific cytokines in pain potentiation and 
propagation in LBP. The commonest targets by far are Tumour Necrosis Factor (TNF), Nerve 
Growth Factor (NGF) and Interleukin-1 (IL-1). Both terms will be used here interchangeably 
in a broad and comprehensive manner. 
TNF-alpha is an important inflammatory mediator that irritates and damages nerve roots. 
Endoneurial injection of TNF-alpha in rodents has been shown to cause vascular and 
histological nerve modifications that are similar to changes seen with extrusion of nucleus 
polposus [16, 17]. The involvement of TNF-alpha in disc herniation, nerve sensitisation and 
ingrowth is further supported by the preventive effects of TNF-alpha blockade in animal 
models of IVD [18, 19]. Local production of TNF-alpha is upregulated in degenerate and 
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herniated discs compared to non-degenerate IVD tissue, and highly sensitive methods have 
enabled the detection of the cytokine within nucleus pulposus, Schwann cells and epidural 
space [20]. These reports provided the rationale for clinical studies evaluating the efficacy of 
TNF-alpha inhibition for discogenic pain in humans [21, 22]. 
In rodents, increased concentrations of NGF and sensitisation of NGF receptors were 
observed in constricted sciatic nerve injury [23, 24]. Significant reduction in inflammatory 
processes, pain and hyperalgesia seen after the injection of anti-NGF subsequently confirmed 
a causal relationship between NGF and chronic constriction sciatic nerve injury [25], 
potentially, through the blockade of peripheral nociceptors [26]. The observed NGF and anti-
NGF effects in the animal models were replicated in humans [27]. Here, upregulation of TNF 
and the production of IL-1 in degenerated or herniated discs, directly induce the expression of 
NGF in the inflamed tissue. Once expressed, NGF contributes to chronic neuronal stimulation 
primarily by binding to tyrosine kinase (TrKA) and p75NTR (75 kDa neurotrophin) receptors 
on sensory neurones, thereby causing post-translational changes in transient receptor 
potential vanilloid 1 (TRPV1). The interaction results in the depolarisation of ion channels 
that detect milieu acidity, which is ultimately perceived as pain. Additionally, NGF recruits 
other pro-inflammatory immune cells such as mast cells [28, 29] thereby exacerbating pain 
perception [30]. Details of these responses have been published elsewhere [31, 32]. 
Whilst clinical research on biologics specifically targeting TNF-alpha and NGF usually focus 
on systemic autoimmune disease and osteoarthritis respectively, the increasing incidence of 
LBP and the unmet need for adequate pain control have led to renewed interest in LBP.  
Accordingly, this review discusses the current knowledge on the use of anti-TNF and anti-
NGF for the management of LBP. 
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[Insert Figure 1 here] 
Methods 
MEDLINE and EMBASE were extensively searched from inception up to March 2017, 
according to published guidance on narrative reviews [33]. A combination of both indexing 
and free-text terms were used, including chronic low back pain, sciatica, anti-TNF, anti-NGF 
and growth factors. Studies that evaluated the use of biologic agents for the management of 
chronic low back pain or sciatica were selected for inclusion. The search was restricted to 
articles published in English language. A hand search of the reference lists of studies meeting 
the inclusion criteria was also performed to identify other relevant papers. Where more than 
one paper from a single trial was identified, information from both papers were pooled and 
the latest version was cited. 
Results 
Anti-Tumour Necrosis Factor (TNF)-α Therapy 
So far, only three anti-TNF medications have shown potential for being scaled-up into routine 
practice: These are infliximab, etanercept and adalimumab. Karppinen et al [34] treated 10 
patients with a 2 to 12-week history of sciatica and magnetic resonance evidence of IVD with 
a single intravenous infusion of infliximab (3mg/kg) and achieved a significant reduction of 
radicular pain score within hours after the effusion (Table 1). The patients did not experience 
any side effects and were able to return to work at 4 weeks without undergoing any invasive 
procedure such as epidural steroid injections or surgery. A follow-up study re-assessing the 
same individuals at 6 and 12 months showed sustained clinical outcomes accompanied by a 
radiological improvement in repeated magnetic resonance in 9/10 patients while the 
remaining one required surgery [35]. Successful administration of infliximab has also been 
reported in case-reports and case series [36]. Another pilot study evaluated the efficacy of 
three etanercept subcutaneous injections (25mg every 3 days) in 10 patients with acute 
sciatica of recent onset – mean duration of symptoms 2.7 ± 1.8 weeks [37]. Leg and back 
pain visual analogue scores improved significantly in all patients on day 10 after treatment 
with one patient suffering a relapse at 3 weeks and treated surgically. In 9 patients beneficial 
effects were noted after 6 weeks. Perispinal delivery of etanercept has also been reported in 
20 patients with improvement of pain and functional status but the heterogeneity of the 
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population including patients with history of spinal surgery and other methodological 
weaknesses limit the validity of the study [38]. 
Despite the encouraging findings of uncontrolled studies, some randomised controlled trials 
(RCTs) failed to provide robust evidence for the efficacy of biological agents targeting TNF-
alpha in subjects suffering from IVD. A single infliximab infusion (5mg/kg) in 21 patients 
had no greater effect compared to 19 controls receiving placebo with regards to intensity of 
pain, function handicap, requirement for surgery or the resorption of disc herniation in 
magnetic resonance imaging over a 6-month period after the treatment [39]. In line with these 
observations epidural administration of etanercept (2 injections separated by 2 weeks) did not 
provide any advantage over epidural saline or steroids in patients with lumbosacral 
radiculopathy in triple blind RCTs [40]. On the other hand Freeman et al [41] demonstrated 
beneficial effects of transforaminal epidural etanercept (2 injections 2 weeks apart) in a 
placebo-controlled trial in 49 patients, observations which concur with previous reports in 
smaller cohorts [42]. A short course of subcutaneous adalimumab given early on severe acute 
sciatica decreased the requirement for back surgery in the adalimumab-treated group 
compared to the control cohort after a 3-year follow-up period [43, 44]. 
The inconsistent reports of controlled studies were confirmed in recently published 
systematic reviews and meta-analyses which showed that, compared to placebo or steroids, 
TNF-alpha inhibition was neither superior in controlling pain and alleviating symptoms nor 
did it increase the proportion of IVD patients returning to work [45, 46]. However, both 
reports demonstrated a reduction of the risk for discectomy in patients treated with biologic 
drugs highlighting that beyond anti-inflammatory, TNF-alpha antagonists may also have 
neuroprotective properties which promote the recovery rate of neurological abnormalities and 
the improvement of functional status. 
 
[Insert Table 1 here] 
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Anti-Nerve Growth Factor (NGF) Therapy 
The reassuring findings from preclinical studies were translated into a number of RCTs that 
aimed to assess the safety and efficacy of a humanised monoclonal antibody (mAb) against 
NGF (Table 2). Tanezumab, fulranumab and regeneron were the anti-NGFs that have been 
evaluated in a clinical trial. No study evaluating regeneron was included in this review 
because none has been published in a peer-reviewed journal. 
In the first published phase II clinical trial of anti-NGF, 88 patients with chronic LBP 
received a single 200µg/kg of Tanezumab IV infusion at baseline and a matching daily oral 
placebo for the treatment duration of 12 weeks [50]. The second cohort of 88 patients 
received a single IV placebo at baseline and a 1000mg daily dose of oral naproxen. The last 
cohort of 41 patients received single IV placebo at baseline and daily oral placebos for the 
treatment duration. The primary outcome was mean change in LBP intensity score from 
baseline to 6 weeks. Katz et al [50] showed that the Tanezumab group had the greatest mean 
reduction in LBP intensity score. The intervention also significantly reduced participants 
Roland Morris Disability Questionnaire (RMDQ) and Patient’s Global Assessment (PGA) 
score. Adverse event rates across the three cohorts were similar, and no serious adverse event 
was reported with Tanezumab. 
Another published study reiterated the efficacy of anti-NGF. In the study, 1347 patients with 
a minimum 3-month history of chronic LBP were randomly assigned to treatment groups 
[51]. Of these, three cohorts of 232, 295 and 295 patients were treated with 5mg, 10mg and 
20mg IV Tanezumab injection respectively at baseline and at eight weeks, all with matching 
daily oral placebo. Another cohort of 230 patients received two doses of IV placebo and daily 
oral placebo. The last cohort (295 patients) received two doses of IV placebo eight weeks 
apart with matching daily dose of naproxen (500mg). The lower doses and the long dose 
interval were due to anti-NGF’s high affinity to bind specific targets and its long terminal 
half-life. The result at 16 weeks revealed that patients on 10mg and 20mg of the study drug 
had a greater reduction in LBP intensity compared with the placebo group and naproxen 
group. There was no significant difference between Tanezumab 5mg versus the placebo or 
naproxen group. Unlike Katz et al., the downside to Kivitiz et al. was that the incidence of 
adverse events was greater in patients who received Tanezumab. A noteworthy point was that 
there was no reported case of osteonecrosis or death. The achieved clinical outcomes were 
maintained in a follow-up open-label study of a subset of these patients.  
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One study however reported a contradictory finding. A five-arm placebo controlled RCT 
evaluated the efficacy of fulranumab, another form of anti-NGF, as an adjunctive therapy in 
patients with moderate-to-severe chronic LBP [52]. There were 88 patients in the placebo 
arm while 311 patients across four separate treatment groups received different strengths of 
the study medication. The first and second treatment group each had 77 patients who received 
1mg and 3mg of subcutaneous fulranumab respectively every four weeks. Group 3 received a 
6mg loading dose at baseline and subsequently received 3mg 4-weekly. 10mg was 
administered to the last group at similar intervals to the previous three groups. It was 
observed that fulranumab did not demonstrably reduce pain intensity compared to placebo at 
week 12. 
A systematic review with meta-analysis reported that the overall evidence supporting the use 
of anti-NGF for reducing LBP intensity score, compared to placebo, was weak at best [53]. 
The meta-analysis component showed a small-to-moderate effect for pain relief and a small 
effect for functional improvement.  
 
[Insert Table 2 here] 
 
10 | P a g e  
 
Discussion 
The ability of biologic agents to inhibit/block crucial steps in the generation and propagation 
of nociceptive acute or chronic LBP means that this class of drugs could have a 
complementary role in the management of LBP where traditional interventions have failed to 
provide adequate relief for patients. Altough preclinical results have shown that anti-TNFs 
and anti-NGFs have the potential to revolutionise pain management, so far, clinical evidence 
has produced divergent results. In that respect it is also important to note that the two classes 
of biologic regimens have been tested in different subgroups of individuals suffering from 
sciatica: anti-TNFs have been predominantly tested in patients with acute or chronic sciatica 
accompanied by radicular pain whilst studies with mAbs against NGF recruited patients with 
chronic non-radicular LBP.   
In the former group the superiority of anti-TNFs over placebo was confirmed in only one 
RCT. Other controlled trials did not demonstrate a statistically significant difference in 
clinical outcomes and systemic reviews and meta-analysis of RCTs, non-RCTs and 
observational controlled studies comparing TNF-inhibitors with placebo and other 
interventions did not provide sufficient evidence to recommend that these agents should be 
routinely used for sciatica [45, 46]. However they indicated a beneficial effect of anti-TNFs 
on leg pain intensity in short term and global effects on the medium term [45] as well as 
reduced risk ratio of discectomy or radicular block at medium term follow-up which however 
was not sustainable at long term follow-up [46]. A network meta-analysis of management 
strategies comparing the clinical effectiveness of different treatment strategies for sciatica 
(grouped into 18 treatment categories), including also economic evaluations suggested that 
biologic agents had the highest probability of being the best option but with very wide 
confidence intervals [55]. These observations clearly reflect the small number of trials and 
the lack of data, underscoring the necessity for larger and better-designed studies. To address 
this need a RCT was recently launched in United Kingdom to evaluate whether injections of 
adalimumab plus physiotherapy were more clinically and cost-effective than placebo plus 
physiotherapy for patients with sciatica but the study was prematurely terminated as a result 
of low recruitment due to operational issues and unwillingness of patients to participate [56]. 
With regards to nonspecific chronic LBP it appears the Tanezumab may be more effective in 
pain control (standarized mean difference [SMD] = -0.44, 95% confidence interval [CI] -0.81 
to -0.07) and improvement of functional status (SMD = -0.26, 95%CI -0.40 to -0.12), however 
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when considering anti-NGFs as a drug class there was a decline in the magnitude of effect more 
significant for pain relief (SMD = -0.29, 95% CI -0.58 to 0.00) than for functional improvement 
(SMD = -0.21, 95%CI -0.37 to -0.05 ) of low back pain [53]. Despite a low to moderate effect 
of Tanezumab in pain relief and functional capacity the findings of this systemic review do not 
support the use of anti-NGFs for the management of chronic nonradicular LPB. 
Collectively the outcomes of RCTs and other observational trials assessing the efficacy of 
biologic agents in chronic LPB have been rather disappointing demonstrating limited clinical 
value for patients suffering from this condition. However the overall quality of evidence in all 
systemic reviews was low because of the high heterogeneity of RCTs indentified in the meta-
analyses associated with the small cohort sizes, the dosage and the route of administration of 
biologics, the duration of treatment or the length of follow-up. In addition, only one RCT [37] 
compared biologics with intravenous steroids providing limited evidence for the superiority of 
anti-TNFs but not compared with epidural steroid injections. Other common confounding 
issues in pain studies such as the input of psychological factors in lower response rates 
particularly in patients with longer duration of symptoms should be also taken into account in 
the interpretation of the findings. The evidence for changing practice in LBP associated or not 
with radicular pain is very low but biologics may have the potential to reduce pain particularly 
when other conservative treatment interventions have failed. Despite their cost, biologics may 
be proven a more cost-effective alternative compared to disc surgery and the high economic 
burden of anti-TNFs may be decreased with the initiation of biosimilars. Clearly further studies 
are warranted but they will require appropriate design and simple procedures to ensure both 
adequate recruitment rates and reliable outcomes.  
More recent advances have identified that several inflammatory mediators (IL-1, IL-1β, IL-6, 
chemokines, prostaglandins) are upregulated in disc herniation tissue and/or the cerebrospinal 
fluid in patients with radicular pain and contribute to the irritation of nerve fibres suggesting 
that TNF-alpha might be only one piece of the puzzle [35]. Biologics with different 
mechanisms of action have been tried in patients with lumbar stenosis and chronic pain. For 
example, epidural application of tocilizumab – an anti-IL-6 receptor monoclonal antibody – 
onto the spinal nerve was more effective in alleviating pain than the application of 
dexamethasone [36]. Elucidating mechanisms of herniation of intervertebral disc-related 
nerve root pain remains a challenge, and future studies should also focus on the role of yet 
unexplored potential causes of pain persistence in a considerable fraction of patients. In a 
porcine model, a combination of TNF-alpha and interleukin-1 inhibition has been reported to 
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be more efficient in reducing the nucleus pulposus-induced effects on nerve conduction 
velocity than single inhibition [37], but dual cytokine inhibition is a largely untested 
intervention in humans. Targeting specific TNF-alpha-dependent responses that contribute to 
non-nociceptive pain such as immune cell recruiting processes, neovascularization and nerve 
ingrowth may represent a better approach than the complete blockage of cytokine signalling 
[12]. The utilisation of sensitive imaging modalities alongside functional measurement 
outcomes is also essential for the identification of structural changes following treatment with 
anti-cytokine agents. 
Conclusion 
Current medical and non-pharmaceutical interventions remain ineffective for patients with 
unresolved or recurrent low back pain, and there is an increasing need for improved 
treatments that may provide a better symptomatic pain relief. Novel insights into the cause 
and pathophysiology of lumbar pain and sciatica suggest that disc herniation leads to an 
injury-induced inflammation, which is the main driver of intraradicular inflammatory 
changes such as oedema and demyelination translated into clinical phenotype of 
radiculopathy. Amongst others TNF-α has an important role in the regulation of 
proinflammatory effects of nucleus pulposus contributing to the local vascular and 
inflammatory alterations characterising sciatica, but until today there is no robust proof for 
the analgesic effect of TNF-α inhibition in this condition. The delineation of molecular 
pathways driving acute and chronic sciatic pain and the deeper understanding of cytokine 
networks and inflammatory cells involved may identify novel therapeutic targets and enable a 
more favourable treatment outcome for these patients. In that respect, the launch of larger and 
better-designed studies may determine specific sub-groups of patients who may benefit from 
administration of TNF-α blockers or other classes of biologic regimens. 
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